Home/Filings/4/0001415889-24-026144
4//SEC Filing

Erck Stanley C 4

Accession 0001415889-24-026144

CIK 0001287098other

Filed

Nov 4, 7:00 PM ET

Accepted

Nov 5, 4:25 PM ET

Size

9.3 KB

Accession

0001415889-24-026144

Insider Transaction Report

Form 4
Period: 2024-11-01
Transactions
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2024-11-0147,6890 total
    Exercise: $0.04Exp: 2024-11-11Common Stock (47,689 underlying)
  • Exercise/Conversion

    Common Stock

    2024-11-01$0.04/sh+47,689$1,908316,807 total
  • Sale

    Common Stock

    2024-11-01$3.72/sh47,689$177,403269,118 total
Footnotes (3)
  • [F1]The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2024. The option that is the subject of the trading plan is scheduled to expire by its terms on November 11, 2024.
  • [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.61 to $3.755, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]This option is fully vested and exercisable.

Issuer

MAXCYTE, INC.

CIK 0001287098

Entity typeother

Related Parties

1
  • filerCIK 0001342826

Filing Metadata

Form type
4
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 4:25 PM ET
Size
9.3 KB